“It is estimated that the global annual sales in the asthma and COPD market are due to increase by over $10 billion US dollars within the next 5 years and then remain flat thereafter. Will you make use of this transforming market & increasing potential before it’s too late?

Through a series of case studies from the leading pharmaceutical companies SMi’s 3rd annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine the mortality levels in asthma and COPD, inspect the emerging novel treatments and drug therapies and highlight the development and use of biomarkers through to the use of clinical endpoint in Asthma & COPD.

This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.

The conference will be chaired by Dr Michael Rudolf (Consultant Respiratory Physician, Ealing Hospital and Past Chairman, British Thoracic Society COPD Consortium) and Neil Barnes (Consultant Respiratory Physician, Barts & The London NHS Trust)”

Registration required:

Yes

Free:

No